Sukumar Nagendran
President and Head of R&D · Taysha Gene Therapies, Inc.
- 2025
- Jul 10, 2026
- 8
Other insiders active in the same stocks
Insiders who reported open-market trades in the last 12 months at the companies Sukumar Nagendran files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
- Alexander Cumbo - $984K in SLDB purchases and sales in the last 12 months
- Sean P. Nolan - $840K in TSHA purchases and sales in the last 12 months
- Kamran Alam - $493K in TSHA purchases and sales in the last 12 months
- David T. Howton - $434K in SLDB purchases and sales in the last 12 months
- Kevin Tan - $330K in SLDB purchases and sales in the last 12 months
- Jessie Hanrahan - $297K in SLDB purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Frequently asked questions
Who is Sukumar Nagendran?
Sukumar Nagendran is a corporate insider, tracked as President and Head of R&D of Taysha Gene Therapies, Inc. (TSHA). InsiderAlpha holds 8 primary Form 4 filings for them, the earliest from 2025, updated as new SEC EDGAR filings are processed.
When did Sukumar Nagendran last file a Form 4?
The most recent primary Form 4 on record is dated 10 July 2026, one of 8 filings going back to 2025.
Has Sukumar Nagendran been buying or selling stock?
Recorded transactions: 0 open-market purchases and 9 open-market sales ($6.13M) across all tracked filings.
